Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
07/2010
07/06/2010US7749516 Immunization of dairy cattle with GapC protein against Streptococcus infection
07/06/2010US7749514 Activatable clostridial toxins
07/06/2010US7749507 Malaria vaccine
07/06/2010US7749505 Immunogenic polypeptides for use in targeted treatment and prevention of cell proliferative disorders associated with respiratory system
07/06/2010US7749502 Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis
07/06/2010US7749500 Antibodies to IL-17 polypeptides and therapeutic uses thereof
07/06/2010US7749499 Immunoglobulin for use in diagnosis, prevention and treatment of neisserial infection; immunootherapeutics
07/06/2010US7749498 Binding native human tissue factor (TF) and does not substantially bind non-native tissue factor; superior anticoagulant activity by binding with high affinity and specificity; reducing cancer cell tissue factor activity and detecting cancer cells that express TF; factor X binding is inhibited
07/06/2010US7749496 Neuronal regeneration
07/06/2010US7749491 Contacting the mammalian cell with at least one adeno-associated virus (rAAV) and at least two agents in an amount effective to additively or synergistically enhance rAAV transduction
07/06/2010CA2522067C Detection, characterization and treatment of viral infection and methods thereof
07/06/2010CA2461199C Atlastin
07/06/2010CA2454863C Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
07/06/2010CA2382129C Novel derivatives of flavones, xanthones and coumarins
07/06/2010CA2298864C Chemical modification of proteins to improve biocompatibility and bioactivity
07/06/2010CA2288059C Method of treating malignancies
07/06/2010CA2218028C Brain edema inhibitor
07/06/2010CA2209360C Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
07/06/2010CA2150785C Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
07/06/2010CA2123049C Pharmaceutical containing the p40 subunit of interleukin 12
07/01/2010WO2010075521A1 Compositions and methods of treating cancer
07/01/2010WO2010075449A1 Mass spectrometry assay for congenital adrenal hyperplasia
07/01/2010WO2010075417A1 Survivin specific t cell receptor for treating cancer
07/01/2010WO2010075416A1 Antibiotic compositions for the treatment of gram negative infections
07/01/2010WO2010075327A1 Desmopressin composition
07/01/2010WO2010075303A1 Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
07/01/2010WO2010075067A2 Methods for diagnosing and treating autoimmune disorders
07/01/2010WO2010075060A2 Methods and compositions for modulating proline levels
07/01/2010WO2010074794A2 Membrane transduction peptides, polynucleotides, and methods
07/01/2010WO2010074591A1 Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action
07/01/2010WO2010074239A1 Microneedle device
07/01/2010WO2010074082A1 Modified vasohibin
07/01/2010WO2010073531A1 Muscle-building agent
07/01/2010WO2010073266A1 Sequence variants predictive of risk of kidney stones and bone mineral density
07/01/2010WO2010073257A1 An immunodominant b-cell epitope based protein vaccine against anthrax and method of preparation thereof
07/01/2010WO2010073104A2 Improving cognitive function
07/01/2010WO2010073009A2 Compounds, compositions and use
07/01/2010WO2010072929A1 Soothing cosmetic or pharmaceutical composition comprising a peptide which activates hmg-coa reductase
07/01/2010WO2010072928A1 Soothing pharmaceutical or cosmetic composition comprising a peptide that activates hmg-coa reductase
07/01/2010WO2010072927A1 Peptides derived from hmg-coa reductase and cosmetic and/or pharmaceutical composition containing same
07/01/2010WO2010072926A1 Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same
07/01/2010WO2010072843A2 Use of a peptide derived from er-alpha for restoring sensitivity to antiestrogenic compounds in breast tumour cells
07/01/2010WO2010072797A1 Compounds and methods for the treatment of autoimmune and inflammatory disease
07/01/2010WO2010072684A1 Norrin in the treatment of diseases associated with an increased tgf-beta activity
07/01/2010WO2010072630A1 Medical use of ribosomal protein s19 (rps19)
07/01/2010WO2010072621A2 Process for the preparation of a peptide powder form
07/01/2010WO2010054316A3 Endothelium mimicking nanomatrix
07/01/2010WO2010053990A3 Crhr2 peptide agonists and uses thereof
07/01/2010WO2010051534A3 Method for apcdd1 mediated regulation of hair growth and pigmentation and mutants thereof
07/01/2010WO2010047928A3 Methods and compositions for treatment of fibrosis
07/01/2010WO2010046461A3 Treatment of intracellular bacterial infections
07/01/2010WO2010039563A3 Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
07/01/2010WO2010039461A3 Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes
07/01/2010WO2010030653A3 Nurr1 interacting protein (nuip)
07/01/2010WO2010027473A3 Immunogenic escherichia coli heat stable enterotoxin
07/01/2010WO2010027404A3 Stable formulation comprising therapeutic polypeptides for oral administration
07/01/2010WO2010024927A3 Treatment of amyloidoses using myelin basic protein and fragments thereof
07/01/2010WO2010022260A3 Novel toxin-antitoxin system
07/01/2010WO2010022089A3 Derivatives of apf and methods of use
07/01/2010WO2010002478A3 Glycopeptide and uses thereof
07/01/2010WO2010000851A3 Methods for modulating angiogenesis via dystrophin dp71
07/01/2010WO2009120619A3 Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
07/01/2010WO2009071903A8 Composition comprising a chondroitin sulphate proteoglycan inhibitory agent and an anti-inflammatory agent
07/01/2010WO2009070298A9 Method of delaying the onset of clinically definite multiple sclerosis
07/01/2010WO2009065007A8 Modified il-4 mutein receptor antagonists
07/01/2010WO2009049234A3 Methods of treating coagulopathy
07/01/2010US20100169989 Use of Follistatin-Like Related Gene (FLRG) to Increase Muscle Mass
07/01/2010US20100169988 Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
07/01/2010US20100169987 Animal model simulating neurologic disease
07/01/2010US20100168807 Bioactive terpolymer compositions and methods of making and using same
07/01/2010US20100168746 Reduced pressure augmentation of microfracture procedures for cartilage repair
07/01/2010US20100168720 System for providing fluid flow to nerve tissues
07/01/2010US20100168689 Systems for providing fluid flow to tissues
07/01/2010US20100168399 Antibodies that bind b7l-1
07/01/2010US20100168381 Conjugates of membrane translocating agents and pharmaceutically active agents
07/01/2010US20100168242 Polymorphs of suberoylanilide hydroxamic acid
07/01/2010US20100168214 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
07/01/2010US20100168209 Apoptosis inducer for cancer cell
07/01/2010US20100168208 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
07/01/2010US20100168207 Compositions and methods for sirna inhibition of angiogenesis
07/01/2010US20100168052 Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
07/01/2010US20100168040 Muscle fatigue remedy
07/01/2010US20100168039 Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
07/01/2010US20100168038 Use of compounds in combination with gamma-irradiation for the treatment of cancer
07/01/2010US20100168037 Peptides comprising aromatic d-amino acids and methods of use
07/01/2010US20100168036 Growth factor
07/01/2010US20100168035 Subcutaneous implants containing a degradation-resistant polylactide polymer
07/01/2010US20100168034 Peptide having cell membrane penetrating activity
07/01/2010US20100168033 Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
07/01/2010US20100168032 Smart Pro-Drugs of Serine Protease Inhibitors
07/01/2010US20100168031 Lat peptides and their use in assays for identifying immunosuppressants
07/01/2010US20100168030 Methods and compositions for treatment of organophosphate-caused pathology
07/01/2010US20100168029 Methods for treating bone tumors
07/01/2010US20100168028 Compositions and methods of using crmp-1 and its fragments for treating cancer
07/01/2010US20100168027 Bpc-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
07/01/2010US20100168026 Insulin secretion inducer, and accelerator for increasing the number of pancreatic beta-cells
07/01/2010US20100168025 Stroke-generated angiogenesis enhancers and uses thereof
07/01/2010US20100168024 Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials
07/01/2010US20100168023 Injectable Botulinum Toxin Formulations
07/01/2010US20100168022 Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens
1 ... 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 ... 3163